By Doug Macron

Tekmira Pharmaceuticals last week announced the publication of data showing that the company's proprietary nucleic acid-delivery technology could be used in conjunction with an RNAi drug to protect non-human primates from a lethal dose of Ebola virus.

The data, Tekmira President and CEO Mark Murray said in a statement, "are the first demonstration that RNAi is efficacious in an otherwise lethal primate infectious disease setting," and support the utility of RNAi in infectious diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.

Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.

The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.

In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.